The LifePort Liver Transporter PILOT clinical trial manuscript has been printed in the May 2024 edition of Hepatology! Panayotova et al. conducted a multicenter, randomized, noninferiority trial which sought to compare liver preservation using LifePort Liver Transporter to the standard of care, static cold storage. Read the full article here: https://bit.ly/3THimZl
Organ Recovery Systems’ Post
More Relevant Posts
-
Retired Member of the Board of Managing Directors at Boehringer Ingelheim | Head of Human Pharma | Member of the Supervisory Board at Munich re | Passionate about Leadership, Innovation and Healthcare
Recently, I had the privilege of meeting a woman who spent decades awaiting a diagnosis for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. This is not just her story. More than 115 million people around the world are living with MASH. Why should we pay attention to this? Due to progressive liver damage that can develop silently, MASH can often go undiagnosed for years. MASH is projected to become the leading cause of liver transplantation by 2030. Each delayed diagnosis is a missed opportunity for early intervention and improved patient outcomes. This underscores the urgent need for innovation in MASH. It is through such advancements that we could transform patient stories from journeys of uncertainty to narratives of hope and healing. Let's continue to push the boundaries of what's possible in healthcare, for the sake of patients worldwide. Today’s announcement of potential best-in-class data is pivotal in our mission to improve the lives of people living with MASH and liver fibrosis. I’m proud of the team for achieving this critical Phase II milestone! #EASLCongress #liverdisease #NEWS
#NEWS: We are thrilled to announce full data from our Phase II trial in adults with metabolic dysfunction-associated steatohepatitis (#MASH) and liver fibrosis stages F1, F2 and F3! The data showed that the trial met all key secondary endpoints, including improvement in fibrosis due to MASH in addition to the primary endpoint. The data were presented today at EASL | The Home of Hepatology | and simultaneously published in The New England Journal of Medicine. #LifeForward #EASLCongress #liverdisease Learn more: https://bit.ly/3XaAtZ4
-
-
We are excited to announce the LifePort Liver Transporter PILOT clinical trial manuscript has been accepted for publication and is now available online! This US multicenter, randomized, non-inferiority trial led by Dr James V Guarrera sought to compare liver preservation using the LLT to the standard of care, static cold storage. The study included 142 liver transplant procedures from 9 US centers, and compared outcomes such as early allograft dysfunction, L-GrAFT7 score, primary nonfunction, biliary strictures, and non-anastomotic biliary strictures. Overall, they concluded that HMP-O2 with LifePort Liver Transporter is safe and efficacious for liver graft preservation compared to SCS. Read the full article here: https://bit.ly/3THimZl
-
-
💖 💖 Welcome to the paper published in the Special Issue in Journal of Clinical Medicine (JCM) MDPI “Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios" by Alfonso Wolfango Avolio et al. 👉 👉 More detail: https://lnkd.in/g23mGN32 💐 💐 Dr. Paolo De Simone led the Special Issue"Developments and Challenges in Liver Transplantat" still open for submissions https://lnkd.in/gNSrS9Jb #liver #transplant
-
-
📣 Attention to everyone attending the 22nd International Congress of ESTIV 2024. Don't miss our Presentation - A Sensitive and Robust Human Liver Microphysiological System for Assessing Drug-Induced Liver Injury. 📅 Date: 4 June 2024, Tuesday 🕣Time: 12:20 pm 📍Track: 3B - Organ-on-a-Chip and Microphysiological Systems Dr. Ovidiu Novac will discuss how our PhysioMimix® OOC liver-on-a-chip demonstrates better sensitivity and specificity over 2D primary hepatocyte culture and even some non-MPS 3D models, when predicting human-specific DILI, matching clinical data to highlight its clinical translatability. 👉 More information: https://bit.ly/3R0gSqz #CNBioAt #ESTIV2024 #OrganOnChip
-
Pathophysiology of policystic liver disease
Excited to announce our latest publication ‘The pathophysiology of polycystic liver disease’ in the Journal of Hepatology . With our snapshot, we simplified the known mechanisms behind polycystic liver disease into a condensed visual that balances detail with easy-to-interpret appeal. Full article: https://lnkd.in/evZP9Fsv A thank you to all the contributing authors Melissa Maria Boerrigter, Tom Gevers, Joost PH Drenth
-
-
Hepatology experts IHEP (International Hepatology Education Program) explore the potential impact of concomitant use of GLP-1 receptor agonists for the better management of non-alcoholic fatty liver disease. Download the article to learn more: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1 #ClinicalTrials
-
-
Chief Scientific Officer at Antaros Medical | Biomarker Innovator, Leader in deploying imaging in clinical trials and a notorious fotball (soccer) coach for the last 20 years.
Want to know more about drug development in Cirrhosis! Check this!
Save the date for our next webinar! Join Quentin M. Anstee (Dean of Research & Innovation and Professor of Experimental Hepatology @ Newcastle University) and Lars Johansson (CSO @ Antaros Medical) as they cover the complexity of cirrhosis, provide insights into drug development in chronic liver disease, and discuss their perspectives on the future. Cracking Cirrhosis: Complexity of chronic liver disease and insights for drug development Tuesday, October 15th at 17:00 CEST (16:00 BST/11:00 EDT) Learn more and register for the webinar here: https://lnkd.in/dZTuBmu6
-
-
The official journal of the Mexican Association of Hepatology, the Latin American Association for the Study of the Liver, the Canadian Association for the Study of the Liver and the Czech Society of Hepatology
🌟 Exciting news from Annals of Hepatology! 🌟 📚 Our latest online publication, "Pathophysiology of Ascites: The Importance of the Intestine. A Surgical Contribution to the Understanding of a Medical Problem" by Gabriel Gondolesi, is now available! 🔍 Dive into this groundbreaking article where the pathophysiology of ascites formation is redefined. Discover how the intestine emerges as a game changer in understanding ascites production. 👩⚕️ Join us in exploring this innovative perspective on ascites and its implications for hepatology. Read the full (free) article here: https://lnkd.in/gWn_b3Rb #Ascites #Hepatology #MedicalResearch #InnovativeInsights #GameChanger 📝💡🔬
-
In case you missed it, Mitchell Shiffman, M.D. discussed the results from our Phase 2b #AHFIRM trial in alcohol-associated #hepatitis (#AH) in a late-breaking oral presentation at the EASL Congress 2024. We're excited to advance into a Phase 3 #ClinicalTrial. See the slides here: https://bit.ly/3Rq8m4E EASL | The Home of Hepatology
-
-
Double vein embolization w/ simultaneous embolization of the portal + hepatic vein aims to grow the future liver remnant in preparation for major hepatectomy Read the full article for more on the transfemoral approach as an alternative option https://lnkd.in/dtc5dfTC #IRad
-
